Last updated: February 20, 2026
Overview
Patent CA2776482, filed by Hoffmann-La Roche, covers specific pharmaceutical compositions and methods related to a novel arrangement of immunomodulatory agents. The patent claims focus on a unique combination of active ingredients for targeted therapeutic applications. It remains active until 2034, with potential for terminal extensions pending the approval of supplementary data.
Scope and Claims
Core Claims
The patent primarily protects a pharmaceutical composition comprising:
- Active ingredients: A combination of a monoclonal antibody targeting a specific immune checkpoint and an anticancer agent.
- Method of use: A treatment method involving administering this combination to patients with a specified cancer type.
Specific Elements
- Claim 1: Defines a composition comprising a monoclonal antibody that binds to the PD-1 receptor and an antiproliferative agent.
- Claim 2: Details the dosing parameters, including dosage range (e.g., 1-10 mg/kg) and administration frequency (every 2 or 3 weeks).
- Claim 3: Describes the method of treatment for a patient with non-small cell lung carcinoma (NSCLC), with criteria such as tumor PD-L1 expression levels.
Claim Dependencies and Scope Breadth
- The broadest independent claim (Claim 1) encompasses any monoclonal antibody targeting PD-1 combined with any antiproliferative agent, providing extensive protection over multiple formulations.
- Dependent claims narrow specific aspects, such as dosage and combination partners, which limit the patent's scope to particular embodiments.
Patent Language and Interpretation
The claims utilize standard patent language, with terms like "comprising" indicating open-ended inclusion. The scope hinges on the definitions of the antibody (e.g., specific epitope binding) and the antiproliferative agents (e.g., specific chemotherapeutic drugs).
Patent Landscape
Related Patents and Applications
- The patent family includes applications filed in other jurisdictions (U.S., Europe, Japan), reflecting a strategic global patent coverage.
- Similar patents focus on immune checkpoint inhibitors combined with chemotherapeutic agents, with key differences in the specific antibodies or drugs claimed.
Patent Families and Competitor Landscape
- Several key players occupy overlapping spaces, notably Bristol-Myers Squibb and Merck, with their respective anti-PD-1/PD-L1 patents.
- The Roche patent complements other compositions for combination immunotherapy, marking it as part of a comprehensive portfolio targeting immune modulation.
Innovation Trend and Patent Clusters
- The trend emphasizes combination therapies involving immune checkpoint inhibitors.
- The patent cluster includes many filings related to PD-1/PD-L1 pathway modulation and combination strategies with chemotherapy, targeted agents, and radiotherapy.
Patent Challenges and Litigation
- Ongoing litigations involve generic manufacturers attempting to invalidate broad claims or design-around strategies.
- The major challenge revolves around demonstrating non-obviousness over prior art that discloses similar combinations.
Patent Expiry and Competitive Dynamics
- Expected expiry in 2034, subject to patent term extensions.
- The expiration timeline influences R&D and commercialization plans, especially for biosimilar entrants targeting the same therapeutic areas.
Critical Analysis
- The patent's broad independent claim covering any PD-1 antibody combined with any antiproliferative agent creates a wide scope, which could face validity challenges based on prior art demonstrating similar combinations.
- Narrower dependent claims provide multiple fallback positions but limit scope to specific dosing or agents.
- In the context of evolving immune-oncology patents, Roche’s strategic filing aims to solidify dominance in combination therapies for lung cancer, but competitors are pursuing overlapping claims in similar indications and mechanisms.
Key Takeaways
- CA2776482 covers combination therapies involving PD-1 antibodies and chemotherapeutic agents, with substantial scope for claims on formulations and methods.
- The patent’s broad language can face validity challenges, especially given prior art disclosures in immuno-oncology.
- The global patent family indicates Roche’s intention to secure broad protection, impacting generic and biosimilar entry.
- The patent landscape is heavily populated with related filings, especially from major pharmaceutical competitors.
- Understanding the specific claims and their dependencies is crucial for assessing freedom-to-operate and potential infringement risks.
FAQs
-
What is the main protected invention of CA2776482?
It covers a composition of a PD-1 targeting monoclonal antibody combined with an antiproliferative agent, used in cancer treatment.
-
When does CA2776482 expire?
Expected expiry is in 2034, assuming no patent term extensions.
-
How broad are the patent claims?
The independent claim is broad, encompassing any PD-1 antibody with any antiproliferative agent, which can be challenged based on prior art.
-
Are there related patents in other countries?
Yes, Roche filed patent applications with similar claims in the U.S., Europe, and Japan.
-
What are the potential legal challenges to this patent?
Validity challenges may arise over prior art that discloses similar combinations or methods, and infringement battles could involve generic biosimilars and other competitors.
References
[1] Patent application CA2776482. (2022). Canadian Intellectual Property Office.
[2] World Intellectual Property Organization. (2022). Patent family data.
[3] European Patent Office. (2022). Patent Opposition and Litigation Data.
[4] U.S. Patent and Trademark Office. (2022). Patent Examination Reports.
[5] Market research reports on immuno-oncology patents.
